hotspot -WSS

hotspot

author：entertainment 2025-09-30 23:20:17 - browse：6

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The UK government moves asylum

leisure time

WSS

Covid isolation guidance eased by the CDC

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Democratic lawmaker calls for 'well

NYC plans to house migrants on an island in the East River

Wikipedia

hotspot

hotspot

Apple is now the first public company to be valued at $3 trillion

How to fix the rural physician shortage in the U.S.

Jerome Adams on the need for new antivirals for Covid

Scientists unlock the key to scar

How to save PrEP access — and even expand it

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Jerome Adams on the need for new antivirals for Covid

Pfizer highlights cancer drugs it thinks could reignite investor interest

Drug repurposing or repositioning? The language matters

An inside look at PIPEs, biotech's buzzy new financing tool

hotspot

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

AstraZeneca loses challenge to Medicare drug price negotiation

Why getting cancer drugs just got harder for rural patients

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

entertainment

hotspot

leisure time

hotspot